Ani Pharmaceuticals (ANIP) Gross Margin (2012 - 2026)

Ani Pharmaceuticals has disclosed Gross Margin across 15 years of filings, most recently posting 62.35% for Q2 2026.

• In Q2 2026, Gross Margin fell 235.0% year-over-year to 62.35%; the TTM figure through Jun 2026 stood at 60.4% (down 66.0% YoY), while the FY2025 annual figure was 61.36%, up 209.0% from the prior year.
• Gross Margin came in at 62.35% for Q2 2026 at Ani Pharmaceuticals, up from 60.59% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 64.7% in Q2 2025 to a low of 46.85% in Q1 2022.
• Average Gross Margin over 5 years is 59.97%, with a median of 60.67% recorded in 2022.
• Year-over-year, Gross Margin tumbled 1650 bps in 2022 and jumped 1784 bps in 2023.
• Over 5 years, Gross Margin stood at 61.45% in 2022, then declined by 3 bps to 59.42% in 2023, then retreated by 3 bps to 57.87% in 2024, then gained by 3 bps to 59.42% in 2025, then gained by 5 bps to 62.35% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 62.35% in Q2 2026, 60.59% in Q1 2026, and 59.42% in Q4 2025.